-
1.发明申请公开(公告)号：US20110212471A1
公开(公告)日：2011-09-01
申请号：US12971715
申请日：2010-12-17
申请人： Aase Handberg , Bente Halvorsen , Pål Aukrust , Mona Skjelland
发明人： Aase Handberg , Bente Halvorsen , Pål Aukrust , Mona Skjelland
CPC分类号： G01N33/6893 , C12Q1/6883 , C12Q2600/106 , C12Q2600/158 , G01N33/543 , G01N2333/70596 , G01N2800/32 , G01N2800/323 , G01N2800/50 , G01N2800/52 , G01N2800/56
摘要： The present invention relates to diagnosis, classification and monitoring of atherosclerotic plaques in an individual using measurement of the concentration of CD36 in a body fluid and/or the plaque as such. The present invention also relates to diagnosing the burden of atherosclerotic plaques in an individual. Furthermore, the invention relates to a method for diagnosing stenosis caused by atherosclerotic plaques. Within the scope of the present invention are also methods for determining the treatment regime of an individual. Kits and oligonucleotides for use in the methods are claimed.
摘要翻译： 本发明涉及通过测量体液和/或斑块中CD36浓度来诊断，分类和监测个体动脉粥样硬化斑块。 本发明还涉及诊断个体动脉粥样硬化斑块的负担。 此外，本发明涉及一种用于诊断由动脉粥样硬化斑块引起的狭窄的方法。 在本发明的范围内也是用于确定个体的治疗方案的方法。 要求使用用于该方法的试剂盒和寡核苷酸。
-
2.发明申请公开(公告)号：US20140371089A1
公开(公告)日：2014-12-18
申请号：US14316521
申请日：2014-06-26
申请人： Aase Handberg , Bente Halvorsen , Pål Aukrust , Mona Skjelland
发明人： Aase Handberg , Bente Halvorsen , Pål Aukrust , Mona Skjelland
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , C12Q1/6883 , C12Q2600/106 , C12Q2600/158 , G01N33/543 , G01N2333/70596 , G01N2800/32 , G01N2800/323 , G01N2800/50 , G01N2800/52 , G01N2800/56
摘要： The present invention relates to diagnosis, classification and monitoring of atherosclerotic plaques in an individual using measurement of the concentration of CD36 in a body fluid and/or the plaque as such. The present invention also relates to diagnosing the burden of atherosclerotic plaques in an individual. Furthermore, the invention relates to a method for diagnosing stenosis caused by atherosclerotic plaques. Within the scope of the present invention are also methods for determining the treatment regime of an individual. Kits and oligonucleotides for use in the methods are claimed.
摘要翻译： 本发明涉及通过测量体液和/或斑块中CD36浓度来诊断，分类和监测个体动脉粥样硬化斑块。 本发明还涉及诊断个体动脉粥样硬化斑块的负担。 此外，本发明涉及一种用于诊断由动脉粥样硬化斑块引起的狭窄的方法。 在本发明的范围内也是用于确定个体的治疗方案的方法。 要求使用用于该方法的试剂盒和寡核苷酸。
-
3.发明申请公开(公告)号：US20100105088A1
公开(公告)日：2010-04-29
申请号：US12525887
申请日：2008-02-04
申请人： Aase Handberg , Bente Halvorsen , Pål Aukrust , Mona Skjelland
发明人： Aase Handberg , Bente Halvorsen , Pål Aukrust , Mona Skjelland
CPC分类号： G01N33/6893 , C12Q1/6883 , C12Q2600/106 , C12Q2600/158 , G01N33/543 , G01N2333/70596 , G01N2800/32 , G01N2800/323 , G01N2800/50 , G01N2800/52 , G01N2800/56
摘要： The present invention relates to diagnosis, classification and monitoring of atherosclerotic plaques in an individual using measurement of the concentration of CD36 in a body fluid and/or the plaque as such. The present invention also relates to diagnosing the burden of atherosclerotic plaques in an individual. Furthermore, the invention relates to a method for diagnosing stenosis caused by atherosclerotic plaques. Within the scope of the present invention are also methods for determining the treatment regime of an individual. Kits and oligonucleotides for use in the methods are claimed.
摘要翻译： 本发明涉及通过测量体液和/或斑块中CD36浓度来诊断，分类和监测个体动脉粥样硬化斑块。 本发明还涉及诊断个体动脉粥样硬化斑块的负担。 此外，本发明涉及一种用于诊断由动脉粥样硬化斑块引起的狭窄的方法。 在本发明的范围内也是用于确定个体的治疗方案的方法。 要求使用用于该方法的试剂盒和寡核苷酸。
-
公开(公告)号：US07192932B1
公开(公告)日：2007-03-20
申请号：US09428458
申请日：1999-10-28
申请人： Kjetil Taskén , Einar M. Aandahl , Pål Aukrust , Bjørn S. Skålhegg , Fredrik Müller , Stig Frøland , Vidar Hansson
发明人： Kjetil Taskén , Einar M. Aandahl , Pål Aukrust , Bjørn S. Skålhegg , Fredrik Müller , Stig Frøland , Vidar Hansson
IPC分类号： A61K31/70 , C07H19/00 , C07D273/00
CPC分类号： A61K31/70
摘要： Pharmaceutical compositions useful for treating immunosuppressive disease and containing compounds capable of inhibiting cAMP-dependent protein kinase A (PKA) as well as use of the same, are described.
摘要翻译： 描述了可用于治疗免疫抑制疾病和含有能够抑制cAMP依赖性蛋白激酶A（PKA）的化合物及其用途的药物组合物。
-
公开(公告)号：US07790738B2
公开(公告)日：2010-09-07
申请号：US10333657
申请日：2001-07-20
申请人： Kjetil Taskén , Michel Moutschen , Souad Rahmouni-Piette , Einar Martin Aandahl , Pål Aukrust , Stig S. Frøland , Christian C. Johansson , Vidar Hansson , Jo Klaveness
发明人： Kjetil Taskén , Michel Moutschen , Souad Rahmouni-Piette , Einar Martin Aandahl , Pål Aukrust , Stig S. Frøland , Christian C. Johansson , Vidar Hansson , Jo Klaveness
IPC分类号： A01N43/40 , A01N43/82 , A01N43/78 , A01N43/56 , A01N43/36 , A01N43/02 , A61K31/435 , A61K31/41 , A61K31/425 , A61K31/40 , A61K31/38 , A61K31/335
CPC分类号： A61K31/6615 , A61K31/18 , A61K31/365 , A61K31/381 , A61K31/405 , A61K31/407 , A61K31/415 , A61K31/5415 , A61K31/675
摘要： The present invention provides a method of treating or preventing a disorder typified by an immunodificiency (e.g. HIV), wherein the patient is administered a COX-2 inhibitor or derivative or pharmaceutically acceptable salt thereof, preferably diisopropylfluorophasphate. L-745337, rofecoxib, NS 398, SC 58125, etodolac, meloxicam, celecoxib or nimesulide, and compositions and products containing the same or use of the same in preparing medicaments and for treatment.
摘要翻译： 本发明提供了治疗或预防以免疫功能为代表的疾病（例如HIV）的方法，其中给予患者COX-2抑制剂或其衍生物或药学上可接受的盐，优选氟代二异丙酯。 L-745337，罗非昔布，NS 398，SC 58125，依托度酸，美洛昔康，塞来考昔或尼美舒利，以及含有该组合物和产品的制备药物和用于治疗的组合物和产品。
-
-
-
-
搜索结果
5 条记录 (耗时 0.024 秒)
